Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.7951
-0.1195 (-13.07%)
At close: Nov 16, 2026, 4:00 PM EST
0.8400
+0.0449 (5.65%)
Pre-market: Nov 17, 2026, 8:35 AM EST

Lineage Cell Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
10.8414.569.58.9514.74.34
Revenue Growth
0.18%53.24%6.19%-39.16%238.70%137.73%
Cost of Revenue
21.1417.8812.8116.380.731.43
Gross Profit
-10.3-3.32-3.31-7.4313.982.92
Selling, General & Admin
20.0818.4618.1713.7722.5118.21
Research & Development
----13.9933.91
Operating Expenses
20.0818.4618.1713.7736.552.13
Operating Income
-30.38-21.78-21.48-21.2-22.52-49.21
Interest & Investment Income
1.551.691.721.630.830
Currency Exchange Gain (Loss)
0.912.15-0.27-1.04-21.49
Other Non Operating Income (Expenses)
24.99-35.861.460.540.070.21
EBT Excluding Unusual Items
-2.93-53.8-18.57-20.08-23.62-47.52
Gain (Loss) on Sale of Investments
0.01-0.01-0.01-0.18-2.193.73
Asset Writedown
--14.84----
Legal Settlements
----3.53--
Other Unusual Items
---0.5-0.52
Pretax Income
-2.92-68.65-18.58-23.28-25.81-43.27
Income Tax Expense
-4.8-5.28--1.80.54-
Earnings From Continuing Operations
1.88-63.37-18.58-21.48-26.35-43.27
Minority Interest in Earnings
-0.12-0.17-0.03-0.010.080.25
Net Income
1.75-63.53-18.61-21.49-26.27-43.02
Net Income to Common
1.75-63.53-18.61-21.49-26.27-43.02
Net Income Growth
------
Shares Outstanding (Basic)
246230200173170165
Shares Outstanding (Diluted)
255230200173170165
Shares Change
10.54%14.95%15.94%1.69%3.22%9.64%
EPS (Basic)
0.01-0.28-0.09-0.12-0.15-0.26
EPS (Diluted)
-0.09-0.28-0.09-0.12-0.15-0.26
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-26.46-19.44-23.66-29.240.65-23.9
Free Cash Flow Per Share
-0.10-0.08-0.12-0.170.00-0.14
Gross Margin
-95.04%-22.80%-34.81%-83.07%95.05%67.15%
Operating Margin
-280.34%-149.62%-226.11%-237.04%-153.17%-1133.63%
Profit Margin
16.18%-436.47%-195.91%-240.20%-178.69%-990.99%
Free Cash Flow Margin
-244.15%-133.56%-249.05%-326.89%4.39%-550.59%
EBITDA
-29.62-21.08-20.87-20.51-21.79-48.34
EBITDA Margin
-273.30%-144.82%-219.70%-229.30%-148.22%-
D&A For EBITDA
0.760.70.610.690.730.87
EBIT
-30.38-21.78-21.48-21.2-22.52-49.21
EBIT Margin
-280.34%-149.62%-226.11%-237.04%-153.17%-
Revenue as Reported
10.8414.569.58.9514.74.34
SEC Filings: 10-K · 10-Q